Trichuris suis therapy in Crohn's disease

Gut

Volumn 54, Issue 1, 2005, Pages 87-90

  Summers, R W ^a   Elliot, D E ^a   Urban Jr , J F ^b   Thompson, R ^a   Weinstock, J V ^a  

^a UNIVERSITY OF IOWA   (United States)

^b BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIPARASITIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HELMINTH; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MALE; OOCYTE; OPEN STUDY; PRIORITY JOURNAL; REMISSION; SAFETY; THERAPY; TREATMENT OUTCOME; TRICHURIS; TRICHURIS SUIS; TRICHURIS SUIS THERAPY;

ADOLESCENT; ADULT; AGED; ANIMALS; CROHN DISEASE; FEMALE; HOST-PARASITE RELATIONS; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRICHURIASIS; TRICHURIS;

EID: 10844224526     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.041749     Document Type: Article

References (16)

1. Elliott DE, Urban JF Jr, Argo CK, et al. Does the failure to acquire helminthic parasites predispose to Crohn's disease? FASEB J 2000;14:1848-55.
2. Sabin EA, Araujo MI, Carvalho EM, et al. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 1996;173:269-72.
3. Borkow G, Leng Q, Weisman Z, et al. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest 2000;106:1053-60.
4. Weinstock JV, Summers R, Elliott DE. Helminths and harmony. Gut 2004;53:7-9.
5. Khan WI, Blennerhasset PA, Varghese AK, et al. Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun 2002;70:5931-7.
6. Elliott DE, Li J, Blum A, et al. Exposure to schistosome eggs protects mice from TNBS colitis. Am J Physiol 2003;284:G385-91.
7. Moreels TG, Nieuwendijk RJ, De Man JG, et al. Concurrent infection with Schistosoma monsoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut 2004;53:99-107.
8. Beer RJ. The relationship between Trichuris trichiura (Linnaeus 1758) of man and Trichuris suis (Schrank 1788) of the pig. Res Vet Sci 1976;20:47-54.
9. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Coorperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
10. Summers RW, Elliott DE, Qadir K, et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003;98:2034-41.
11. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharm Ther 2002;16:399-406.
12. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330-8.
13. Panaccione R, Canadian Consensus Group on the use of infliximab in Crohn's disease. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. Can J Gastroenterol 2001;15:371-5.
14. Feagan B. Infliximab in the treatment of Crohn's disease. Can J Gastroenterol 2000;14(suppl C):6C.
15. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98:1010-20.
16. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.